Mirum Pharmaceuticals Inc Revenue Growth Rates (MIRM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Mirum Pharmaceuticals Inc   (NASDAQ: MIRM)
 

MIRM's Revenue Growth by Quarter and Year

Mirum Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MIRM/growth
https://api.csimarket.com/api/v1/companies/MIRM/fundamentals
https://api.csimarket.com/api/v1/companies/MIRM/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
MIRM Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 185.72
2nd Quarter June 176.24
1st Quarter March 159.88
FY 521.84

MIRMs Annual Revenue
Mirum Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 521.31 millions
Mirum Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 336.89 millions
Mirum Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 186.37 millions
Mirum Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 77.06 millions
Mirum Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 19.14 millions




MIRM Revenue third quarter 2026 Y/Y Growth Comment
Mirum Pharmaceuticals Inc reported Revenue improvement of 39.63% year on year in the third quarter 2026, to $ 185.72 millions, this is lower than Mirum Pharmaceuticals Inc 's recent average Revenue surge of 138.19%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 65 other companies have achieved higher Revenue growth. While Mirum Pharmaceuticals Inc ' s Revenue rise of 39.63% ranks overall at the positon no. 603 in the third quarter 2026.


MIRM Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 39.63 %
2nd Quarter June 37.91 %
1st Quarter March 43.27 %
FY   -

Financial Statements
Mirum Pharmaceuticals Inc 's third quarter 2026 Revenue $ 185.72 millions MIRM's Income Statement
Mirum Pharmaceuticals Inc 's third quarter 2025 Revenue $ 133.01 millions Quarterly MIRM's Income Statement


MIRM Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.38 %
2nd Quarter June 10.23 %
1st Quarter March 7.35 %
FY (Year on Year)   -


Back to MIRM Growth rate Comparisons >> Back to MIRM Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #66
Healthcare Sector #142
Overall #603

Revenue Y/Y Growth Statistics
High Average Low
789.29 % 138.19 % 37.92 %
(Jun 30 2023)   (Jun 30 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #66
Healthcare Sector #142
Overall #603
Revenue Y/Y Growth Statistics
High Average Low
789.29 % 138.19 % 37.92 %
(Jun 30 2023)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Mirum Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
310.83 % 25.7 % -54.55 %
(Mar 31 2022)  


MIRM's III. Quarter Q/Q Revenue Comment
Mirum Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.38% quarter on quarter, to $ 185.72 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 4.08% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Mirum Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 802.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #123
Overall #802
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #54
Healthcare Sector #123
Overall #802
Revenue Q/Q Growth Statistics
High Average Low
310.83 % 25.7 % -54.55 %
(Mar 31 2022)  


MIRM's III. Quarter Q/Q Revenue Comment
Mirum Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.38% quarter on quarter, to $ 185.72 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 4.08% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Mirum Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 802.


Mirum Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 670.78
Y / Y Revenue Growth (TTM) 42.18 %
Year on Year Revenue Growth Overall Ranking # 276
Seqeuential Revenue Change (TTM) 8.53 %
Seq. Revenue Growth (TTM) Overall Ranking # 1223


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Mirum Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 671 millions, company would post below average annual Revenue growth of 8.53% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Mirum Pharmaceuticals Inc 's Revenue growth from the 176.24% growth in Jun 30 2026.

In the Healthcare sector 73 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 70 to 276.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 76
Healthcare Sector # 74
Overall # 276

Revenue TTM Y/Y Growth Statistics
High Average Low
200.62 %
 107.69 %
44.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 76
Sector # 219
S&P 500 # 1223
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Mirum Pharmaceuticals Inc 's cumulative twelve months Revenue were $ 671 millions, company would post below average annual Revenue growth of 44.02% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Mirum Pharmaceuticals Inc 's Revenue growth from the 176.24% growth in Jun 30 2026.

In the Healthcare sector 73 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 70 to 276.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 76
Healthcare Sector # 74
Overall # 276

Revenue TTM Y/Y Growth Statistics
High Average Low
200.62 %
107.69 %
44.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 76
Sector # 219
S&P 500 # 1223




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MIRM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions


About Mirum Pharmaceuticals Inc Revenue Growth Rates (MIRM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Mirum Pharmaceuticals Inc (CIK 1759425).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001759425-26-000062
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Mirum Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.